What type of diabetes does streptozotocin induce?

What type of diabetes does streptozotocin induce?

Streptozotocin-induced diabetic murine models develop type 1 diabetes, due to the cytotoxic glucose analogue streptozotocin (STZ) that is toxic to pancreatic β-cells and causes insulin deficiency.

What is the use of streptozotocin?

Usage. Streptozotocin is approved by the U.S. Food and Drug Administration (FDA) for treating metastatic cancer of the pancreatic islet cells. Since it carries a substantial risk of toxicity and rarely cures the cancer, its use is generally limited to patients whose cancer cannot be removed by surgery.

What is streptozotocin induced diabetic mice?

Streptozotocin (STZ) is an antibiotic that can cause pancreatic β-cell destruction, so it is widely used experimentally as an agent capable of inducing insulin-dependent diabetes mellitus (IDDM), also known as type 1 diabetes mellitus (T1DM).

Does alloxan cause diabetes in humans?

The beta cell toxic action of alloxan is initiated by free radicals formed in this redox reaction. Studies suggests that alloxan does not cause diabetes in humans.

Is streptozotocin an antibiotic?

Streptozocin. Streptozocin is a naturally occurring anticancer antibiotic that has a mechanism of action similar to that of nitrosoureas.

Is streptozotocin a drug?

Drug type: Streptozocin is an anti-cancer (“antineoplastic” or “cytotoxic”) chemotherapy drug.

What is alloxan diabetes?

Alloxan-induced diabetes is a form of insulin-dependent diabetes mellitus that occurs as a result of alloxan administration or injection to animals [78], [79]. It has been successfully induced in a variety of animal species; rabbits, mice, rats, monkeys, cats and dogs [80], [81].

What is a long term side effect of carmustine?

Carmustine can increase your risk of bleeding or infection. You will need frequent medical tests. Your cancer treatments may be delayed based on the results. Carmustine can have long-lasting effects on your body.

Does streptozotocin cause diabetes mellitus?

Streptozotocin-induced diabetic models in mice and rats Streptozotocin (STZ) is an antibiotic that can cause pancreatic β-cell destruction, so it is widely used experimentally as an agent capable of inducing insulin-dependent diabetes mellitus (IDDM), also known as type 1 diabetes mellitus (T1DM).

What can we learn from streptozotocin-induced diabetic rats?

This review aimed to gather information about pathophysiological mechanisms and fetal outcomes in streptozotocin-induced diabetic rats. To understand the pathophysiological mechanisms and factors involved in diabetes, the use of pancreatic regeneration studies is increasing in an attempt to understand the behavior of pancreatic beta cells.

What is streptozotocin (STZ) used for?

Streptozotocin (STZ) is an antibiotic that causes pancreatic islet β-cell destruction and is widely used experimentally to produce a model of type 1 diabetes mellitus (T1DM). Detailed in this article are protocols for producing STZ-induced insulin deficiency and hyperglycemia in mice and rats.

Is streptozotocin a carcinogen?

CAUTION: STZ should be handled with care, as it is a know carcinogen. Streptozotocin (STZ) is a highly selective pancreatic islet β-cell-cytotoxic agent that is often administered at a single high dose to cause, within 48 hr, complete β-cell necrosis and diabetes (Kolb, 1987; also see Alternate Protocol ).

https://www.youtube.com/watch?v=k3fLgV90BSw